Clinical depression resident survival guide: Difference between revisions
Line 334: | Line 334: | ||
*[[Milnacipran]]<br> | *[[Milnacipran]]<br> | ||
*[[Desvenlafaxine]] | *[[Desvenlafaxine]] | ||
|<br>75-300<br>20-60<br>50-200| | |<br>75-300<br>20-60<br>50-200 | ||
| | |||
*Mild [[anticholinergic]] effect | |||
*[[Drowsiness]] | |||
*[[Gastrointestinal tract|GI]] distress | |||
|- | |- | ||
|'''Non adrenaline and Specific Serotonin Inhibitor''' | |'''Non adrenaline and Specific Serotonin Inhibitor''' | ||
Line 347: | Line 351: | ||
*[[Trazodone]]<br> | *[[Trazodone]]<br> | ||
*[[Nefazodone]]| | *[[Nefazodone]]| | ||
|<br>150-300<br>100-300| | |<br>150-300<br>100-300 | ||
| | |||
*[[Anticholinergic effect]] | |||
*[[Drowsiness|drowsiness]] | |||
*[[Weight gain]] | |||
*Conduction abnormality | |||
|- | |- | ||
|'''Mono amine oxidase Inhibitors''' | |'''Mono amine oxidase Inhibitors''' |
Revision as of 18:11, 29 October 2020
Clinical depression Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rinky Agnes Botleroo, M.B.B.S.
Synonyms and keywords:
Overview
Depression often leads to poor quality of life and impaired functioning.Clinical depression is defined as loss of interest (anhedonia) and/or depressed mood for 02 or more weeks with atleast 4 of the following features such as, sleep disturbances, loss of appetite/increased appetite,feeling guilty/worthless,loss of energy, loss of concentration,psychomotor retardation, suicidal ideation.The pathophysiology of depression is not incompletely understood.But it is thought that decreased levels of monoaminergic neurotransmitters like Dopamine, Serotonin and Nor-epinephrine are responsible for low mood. When a patient with depressed mood comes to primary care a detailed psychiatric interview is important to evaluate the psychiatric symptoms and assess the effect of symptoms on functioning of the patient.A physician is required to give the patient enough time to build a good doctor-patient relationship and to establish an effective therapeutic alliance with the patient and a physician should give attention to matters of a sensitive nature.If needed family and friends of the patient may be involved and cultural, social, and situational factors should be considered to diagnose the triggering factors as well.
Causes
Life Threatening Causes
Life-threatening causes include conditions includes:
Common Causes
- Genetic Predisposition
- Life Experiences
- Divorce or the end of a serious relationship
- Eating disorders
- Financial difficulties or poverty
- Gambling addiction
- Grief over the death of a child, spouse, other family members, or friends.
- Job loss or unemployment
- Loss of religious faith[1]
- Ongoing major health problems
- Medical Conditions
- Cardiovascular disease[2]
- Hepatitis[3]:There is a high prevalence of depression in patients with hepatitis B and hepatitis C infection, especially those who are on Interferon therapy.
- Mononucleosis[4][5]
- Hypothyroidism[6]
- Sleep apnea[7]
- Fructose malabsorption[8]
- Parkinson disease[9]
- Multiple Sclerosis [10]
- Hormonal contraception[11]
- Steroids
- Addison's disease[12]
- Syphilis
- Post- stroke[13]
- Thyrotoxicosis
- Diabetes Mellitus
- Attention-Deficit/Hyperactivity Disorder (ADHD)[14]
- Dietary
- Seasonal Affective Disorder: Due to production of excessive melatonin
- Postpartum Depression
- Drugs:[16]
- Cardiovascular drugs:ACEI,Calcium Channel blockers,Digitalis,Clonidine, Hydralazine,Methyl-dopa, Procainamide,Propanolol,Thiazide and Zolamide diuretics, Reserpine
- Anti-parkinsonian drugs: Levodopa, Amantadine, Bromocriptine
- Anti-convulsants:Ethosuximide, Phenobarbital, Phenytoin,Vigabatrin,Tiagabine
- Anti-psychotic: Fluphenazine,Haloperidol
- Chemotherapeutics:Azathioprine, Bleomycin, Cisplatin,Cyclophosphamide, Vinblastine, Vincristine
- Stimulants: Amphetamine withdrawal, Cocaine withdrawal
- Anti-retroviral:Atazanavir,Efavirenz, Zidovudine, Saquinavir
- Sedative and anxiolytics: Barbiturates, Ethanol, Benzodiazepines
Diagnosis
Shown below is an algorithm summarizing the diagnosis of Clinical Depression[16][17][18]
Patient with Clinical Depression | |||||||||||||||||||||||||
Take complete history | |||||||||||||||||||||||||
Do initial screening | |||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||
Repeat Screening Annually | |||||||||||||||||||||||||||||||||||
Ask the following questions about last 2 weeks: ❑ Do you feel low/ hopeless or sad? ❑ Do you feel guilty about anything?Do you Feel bad about yourself—or that you are a failure or have let yourself or your family down ❑ Do you feel tired/ fatigued most of the time of the day? ❑ Can you concentrate on usual work? Are you having trouble concentrating on things, such as reading the newspaper or watching television ❑ Have you noticed any changes in appetite? ❑ Have you been moving or speaking so slowly that other people could have noticed? Or the opposite—being so fidgety or restless that you have been moving around a lot more than usual ❑ Have you had any thoughts of death and/or suicide, suicide planning, or a suicide attempt | |||||||||||||||||||||||||
General Physical Examination: ❑ Look for thyroid swelling ❑ Look for symptoms of malnutrition and specific nutritional deficiency | |||||||||||||||||||||||||
Perform mental status examination: ❑ Level of consciousness: See if patient reacts to stimuli ❑ Appearance and general behavior:Look for patient's physical appearance, grooming (clean/untidy or dishevelled appearance), dress (subdued/riotous), posture (erect/kyphotic) ❑Speech and motor activity:Ask them open-ended questions and check if there is any word-finding difficulties, or the rapid and pressured speech, tics or unusual mannerisms,Look for slowness and loss of spontaneity in movement,Look for akathisia or motor restlessness ❑ Affect and mood:Look for restricted, labile, or flat affect ❑ Thought and Perception: Evaluate how the patient perceives and responds to stimuli. Does the patient harbor realistic concerns, or are these concerns elevated to the level of irrational fear? Is the patient responding in exaggerated fashion to actual events, or is there no discernible basis in reality for the patient's beliefs or behavior? Look for illusions, Hallucinations ❑ Attitude and Insight:See if the patient gets angry, aggressive,hostile, overdramatic,helpless during interview ❑ Cognitive abilities:Attention,Language,Memory,Constructional ability and praxis,Abstract reasoning | |||||||||||||||||||||||||
Establish a diagnosis | |||||||||||||||||||||||||
Differential diagnosis by ruling out secondary depression | |||||||||||||||||||||||||
Rule out Bipolar disorder, Premenstrual dysphoric disorder | |||||||||||||||||||||||||
Assessment: ❑ Assess the severity of the disease ❑ Assess their level of functioning: Ask if there is any work dysfunction ❑ Do detailed Physical examination to rule out any disease that can contribute to depression | |||||||||||||||||||||||||
Do basic investigations: ❑ Haemoglobin ❑ Blood sugar ❑ Lipid levels ❑ Liver function test ❑ Renal function test ❑ Thyroid function test ❑ Urine pregnancy test(If required) | |||||||||||||||||||||||||
Ask about previous treatment history: ❑ Ask if they have any past medical illness ❑ Ask if they take any medications ❑ Ask about response to any prior treatment of depression (if they recieved any treatment earlier) | |||||||||||||||||||||||||
Treatment
Shown below is an algorithm summarizing the treatment of Clinical depression:
Abbreviations: ECT: Electroconvulsive Therapy,MAOI= Monoamine oxidase Inhibitor, TCA= Tricyclic Antidepressant,SSRI= Selective Serotonin Reuptake Inhibitor
Presumptive diagnosis of Clinical Depression | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Determine the level of severity and functional impairment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is referral to mental health care indicated?: ❑ Unclear diagnosis ❑ Need for psychosocial interventions ❑ Patient preference | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discuss Treatment Options and patient's preferences | Refer to Mental health specialty care | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initiate treatment according to severity and follow-up in 1-2 weeks
| |||||||||||||||||||||||||||||||||||||
Follow up in 2 weeks: ❑ Symptoms improved | |||||||||||||||||||||||||||||||||||||
Yes | No | Modify treatment: ❑ Increase dose | |||||||||||||||||||||||||||||||||||
❑ Continue current treatment ❑Re-assess in 4-6 weeks | Some indications for inpatient care: ❑ Presence of suicidal ideation | ||||||||||||||||||||||||||||||||||||
Yes | |||||||||||||||||||||||||||||||||||||
Mild to Moderate Depression
The algorithm below shows the management plan in brief in case of mild, moderate, and severe depression:
Mild to moderate Depression | |||||||||||||||||||||||||||||||||||||||||||||
Remission | Psychotherapy | Pharmacotherapy | Remission | ||||||||||||||||||||||||||||||||||||||||||
No response | No response | ||||||||||||||||||||||||||||||||||||||||||||
Change to Anti-depressant | Partial Response | Change to Anti-depressant OR, Switch to psychotherapy | |||||||||||||||||||||||||||||||||||||||||||
Optimize the treatment: ❑ Increase frequency of psychotherapy | |||||||||||||||||||||||||||||||||||||||||||||
Change or give Combination therapy: ❑ If patient is getting psychotherapy: Add antidepressant | |||||||||||||||||||||||||||||||||||||||||||||
Augmentation/Combination: ❑ If patient is recieving antidepressant:Add a second antidepressant OR augment the medication depending on tolerability and side effects | |||||||||||||||||||||||||||||||||||||||||||||
Severe Depression
The algorithm below shows the management plan in brief in case of severe depression:
Severe Depression | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assess the patient: ❑ Ask about patient's preference of treatment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ECT+Pharmacotherapy | Pharmacotherapy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No response | Partial response | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No further response: ❑ Switch to a different antidepressant from same or different pharmalogical class | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medications
Medications used to treat Depression:[16]
Mechanism | Name | Dose | Side effects |
---|---|---|---|
Selective Serotonin Reuptake Inhibitor | 20-80 20-60 50-300 50-200 20-40 10-20 |
||
Tricyclic antidepressant | 50-200 75-300 75-300 75-300 |
| |
Norepinephrine Serotonin Reuptake Inhibitor | 75-300 20-60 50-200 |
| |
Non adrenaline and Specific Serotonin Inhibitor |
|
15-45 |
Mild anticholinergic effect, drowsiness,GI distress |
Atypical antidepressant | 150-300 100-300 |
| |
Mono amine oxidase Inhibitors | 45-90 30-60 20-60 |
orthostatic hypotension, headache,insomnia,drowsiness | |
Selective Serotonin Reuptake Inhibitor | 20-40 | Diarrhea, nausea, vomiting, insomnia |
Do's
- If the patient has any suicidal ideation, the physician should ask about if he has any plan to execute it or if he has any previous attempts. If they have any specific plan, admit the patient.
- If any patient tells they want to hurt someone, the physician should inform that person as well as to police authority.
- Be empathetic to the patient and listen to them.
- Motivate them to continue the treatment for the long term and help them with medication adherence
Don'ts
- Do not let the patient stay alone and do not keep firearms if they are suicidal.
References
- ↑ NJC Andreasen (1972), "The role of religion in depression", Journal of Religion and Health, Springer
- ↑ Manev R, Manev H (2004). "5-Lipoxygenase as a putative link between cardiovascular and psychiatric disorders". Crit Rev Neurobiol. 16 (1–2): 181–6. doi:10.1615/critrevneurobiol.v16.i12.190. PMID 15581413.
- ↑ Alian S, Masoudzadeh A, Khoddad T, Dadashian A, Ali Mohammadpour R (2013). "Depression in hepatitis B and C, and its correlation with hepatitis drugs consumption (interfron/lamivodin/ribaverin)". Iran J Psychiatry Behav Sci. 7 (1): 24–9. PMC 3939977. PMID 24644496.
- ↑ Senior, Kathryn (1999). "Anecdotal link between mononucleosis and depression disproved". The Lancet. 353 (9148): 214. doi:10.1016/S0140-6736(05)77225-1. ISSN 0140-6736.
- ↑ White PD, Lewis SW (July 1987). "Delusional depression after infectious mononucleosis". Br Med J (Clin Res Ed). 295 (6590): 97–8. doi:10.1136/bmj.295.6590.97-a. PMC 1246972. PMID 3113655.
- ↑ Dayan CM, Panicker V (September 2013). "Hypothyroidism and depression". Eur Thyroid J. 2 (3): 168–79. doi:10.1159/000353777. PMC 4017747. PMID 24847450.
- ↑ Jehan S, Auguste E, Pandi-Perumal SR, Kalinowski J, Myers AK, Zizi F, Rajanna MG, Jean-Louis G, McFarlane SI (2017). "Depression, Obstructive Sleep Apnea and Psychosocial Health". Sleep Med Disord. 1 (3). PMC 5836734. PMID 29517078.
- ↑ Ledochowski M, Sperner-Unterweger B, Widner B, Fuchs D (June 1998). "Fructose malabsorption is associated with early signs of mental depression". Eur. J. Med. Res. 3 (6): 295–8. PMID 9620891.
- ↑ Marsh L (December 2013). "Depression and Parkinson's disease: current knowledge". Curr Neurol Neurosci Rep. 13 (12): 409. doi:10.1007/s11910-013-0409-5. PMC 4878671. PMID 24190780.
- ↑ Siegert RJ, Abernethy DA (April 2005). "Depression in multiple sclerosis: a review". J. Neurol. Neurosurg. Psychiatry. 76 (4): 469–75. doi:10.1136/jnnp.2004.054635. PMC 1739575. PMID 15774430.
- ↑ Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø (November 2016). "Association of Hormonal Contraception With Depression". JAMA Psychiatry. 73 (11): 1154–1162. doi:10.1001/jamapsychiatry.2016.2387. PMID 27680324.
- ↑ Abdel-Motleb M (October 2012). "The neuropsychiatric aspect of Addison's disease: a case report". Innov Clin Neurosci. 9 (10): 34–6. PMC 3508960. PMID 23198275.
- ↑ Paolucci S (February 2008). "Epidemiology and treatment of post-stroke depression". Neuropsychiatr Dis Treat. 4 (1): 145–54. doi:10.2147/ndt.s2017. PMC 2515899. PMID 18728805.
- ↑ Knouse LE, Zvorsky I, Safren SA (December 2013). "Depression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): The Mediating Role of Cognitive-Behavioral Factors". Cognit Ther Res. 37 (6): 1220–1232. doi:10.1007/s10608-013-9569-5. PMC 4469239. PMID 26089578.
- ↑ Rao TS, Asha MR, Ramesh BN, Rao KS (April 2008). "Understanding nutrition, depression and mental illnesses". Indian J Psychiatry. 50 (2): 77–82. doi:10.4103/0019-5545.42391. PMC 2738337. PMID 19742217.
- ↑ 16.0 16.1 16.2 Gautam S, Jain A, Gautam M, Vahia VN, Grover S (January 2017). "Clinical Practice Guidelines for the management of Depression". Indian J Psychiatry. 59 (Suppl 1): S34–S50. doi:10.4103/0019-5545.196973. PMC 5310101. PMID 28216784.
- ↑ Kroenke K, Spitzer RL, Williams JB (September 2001). "The PHQ-9: validity of a brief depression severity measure". J Gen Intern Med. 16 (9): 606–13. doi:10.1046/j.1525-1497.2001.016009606.x. PMC 1495268. PMID 11556941.
- ↑ "The Mental Status Examination - Clinical Methods - NCBI Bookshelf".